BIOMAT Database Logo BIOMAT Database Logo

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. 1990

K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
Department of Internal Medicine (Cancer Research), University of Essen Medical School, Federal Republic of Germany.

Estrogen deprivation by aromatase inhibition is an effective treatment in breast cancer. Between October 1986 and March 1988, 91 postmenopausal patients with advanced breast cancer entered a phase II study performed jointly in three center to investigate the new aromatase inhibitor 4-hydroxyandrostenedione. Patients received 500 mg 4-hydroxyandrostenedione intramuscularly (IM) every 2 weeks for 6 weeks, and 250 mg every 2 weeks thereafter. There were two complete (CRs) and 19 partial remissions (PRs) (response rate, 23%). Disease stabilization (no change; NC) was seen in 26 patients, and in 44 patients (48%), disease progression occurred. Duration of the CRs is 20+ months, median durations of PR and NC are 13+ and 8 months, respectively. Receptor status, relapse-free interval, and sites of metastatic lesions did not appear to influence treatment results. However, efficacy of previous tamoxifen treatment favorably predicted response to 4-hydroxyandrostenedione. Serum estradiol levels decreased significantly in patients after 2 weeks of treatment. Side effects were mostly nonspecific and of low degree, requiring discontinuation of treatment in only 3% of the patients. We conclude that aromatase inhibition with 4-hydroxyandrostenedione is efficacious in the treatment of postmenopausal breast cancer.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005860 Germany, West The former Federal Republic of Germany which was reunified with the former German Democratic Republic in 1990. Federal Republic of Germany,Germany, Federal Republic of
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
September 1986, Cancer research,
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.
January 1987, Steroids,
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
December 1984, Lancet (London, England),
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
January 1990, Cancer chemotherapy and pharmacology,
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
September 1992, The Journal of steroid biochemistry and molecular biology,
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
January 1992, European journal of cancer (Oxford, England : 1990),
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
July 1992, British journal of cancer,
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer].
April 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.
December 2015, European journal of cancer (Oxford, England : 1990),
K Höffken, and W Jonat, and K Possinger, and M Kölbel, and T Kunz, and H Wagner, and R Becher, and R Callies, and P Friederich, and W Willmanns
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
April 1987, Cancer research,
Copied contents to your clipboard!